R1 Therapeutics’ new biotechnology comes with fresh support and a new condition to facilitate the treatment of long-term kidney problems.
Biotech funding rounds can sometimes overlap: a new company starts up, investors pile in, a promising molecule gets another shot in the clinic. But often, there seems to be a deal because it points to a problem that patients have been living with for years while the market largely looked elsewhere.
This is the legend R1 Therapists tries to say. The clinical-stage biotech has launched more than $77.5 million in funding to advance AP306, a drug candidate for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.1). The round was led by Abingworth, F-Prime and DaVita Venture Group with participation from Curie.Bio, SymBiosis and US Renal Care.
Along with the funding, R1 also announced an exclusive global licensing agreement with Alebund Pharmaceuticals outside of China, which gives the company the rights to develop and commercialize AP306 internationally.
Hyperphosphatemia is a word that most people outside of nephrology hear often. But for many people on dialysis, it is part of everyday life.
When the kidneys stop filtering properly, phosphate can build up in the blood. Over time, this excess can contribute to bone problems and cardiovascular problems, adding to the burden of health that comes with advanced kidney disease.
The company says more than 500,000 people in the United States and about four million worldwide receive dialysis. However, even with current therapy, more than 40% of US patients do not achieve phosphate control goals.
This number says a lot. It tells us that this is a medical and usability issue. A treatment can be around for decades and still fail people if it’s too heavy, uncomfortable, or too difficult to maintain day after day.
Current phosphate-lowering treatments, known as phosphate binders, have been the standard of care for nearly 60 years. They work, but often at a cost: low binding capacity, gastrointestinal side effects, and a high medication burden that can make adherence feel like a second full-time job.
This is the priceless truth of chronic disease management. Sometimes, science is not the only obstacle. Sometimes, the barrier requires only the already exhausted patients.
R1 offers AP306 as another type of response. Instead of trying to take up phosphate after it’s already in the digestive tract, AP306 is designed to block its active absorption. If phosphate connectors are like trying to catch water after spilling it on the floor, the AP306 aims to turn off the faucet before the mess starts.
This is a scientific difference, but the human difference may be even more important. If the drug works as hoped, it could effectively lower phosphate while reducing the number of pills patients need to take.
For a patient population already dealing with a dialysis schedule, dietary restrictions, and multiple medications, this is no small upgrade in quality of life. It’s the kind of practical innovation that could change whether a treatment works beyond a clinical trial.
Dr. Krishna Polu, Co-Founder, President and CEO of R1 Therapeutics, noted that they are supported by a strong and experienced syndicate, including DaVita and US Renal Care, who have positioned them as globally recognized providers focused on transforming kidney care.
AP306 represents a radical change in the treatment of hyperphosphatemia by targeting three phosphate transporters in the gastrointestinal tract to block active transport. Early clinical data show that the drug can provide better results and significantly reduce the number of pills patients need to take compared to traditional packages. Paulu further suggested that if successful, AP306 is expected to set a new industry standard and emerge as the main treatment for managing high phosphate levels.
It’s an ambitious framework, and rightly so, but it also deserves the usual biotech caveat: “potential” does a lot of work here. Early promise is not the same as late stage proof. However, in an industry where incrementalism has long been tolerated, even a sure shot at a better mechanism can feel like real change.
The Series A proceeds will fund R1’s global development program for AP306, including a Phase 2b study expected to begin later this year in collaboration with Alebund.
This upcoming trial is important because it will test whether the early clinical signal of the drug can be kept under stricter control. AP306 has already been evaluated in a phase 2a study in dialysis patients, where the company says it showed significant reductions in serum phosphate levels with safety and good tolerability.
However, what makes this funding significant is not just the size of the round. He showed it. The involvement of DaVita Venture Group and US Renal Care suggests that this is not just a story of venture capital chasing innovation. It is a strategic imperative for stakeholders to understand what the current system requires of patients and where it consistently fails.
In longevity and healthy aging, we often celebrate monthly cures, but some of the most important gains can come from smaller advances. Fewer pills, fewer complications, fewer barriers between treatment and real-life compliance.
Kidney disease is rarely portrayed as a longevity story, although it should be. CKD is strongly associated with aging. It increases the risk of cardiovascular disease, accelerates frailty, increases hospitalizations, and narrows the margin of endurance that determines longevity. In other words, it’s not just about surviving kidney failure; it’s about how meaningfully a person can live life while managing it. Therefore, starting R1 is larger than a single asset.
Photo courtesy of R1 Therapeutics
(1) https://r1therapeutics.com/newsroom/press-releases/r1-therapeutics-launches-series-a
